DLDave Lemberg

Dave Lemberg

*This is an algorithmically generated author record based on publicly available information.

Dave Lemberg has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Mistaken Identity: A Prevalence Study of Bromazolam in the American Great Lakes Region

    by Chris S. Thomas, Corey Widman, Ankita Mondal, Matthew Levitas, Bridget Lorenz Lemberg, Dave Lemberg

    Bromazolam (BRZ) is a novel psychoactive substance benzodiazepine drug that has recently emerged within the illicit drug supply in the United States. BRZ is not FDA-approved and is distributed in drug mixtures or as counterfeit "Xanax". We explored the BRZ prevalence from oral fluid samples submitted to our lab for testing. BRZ-positive sample results were examined between August 2024 and November 2025. Illicit drug and other benzodiazepine content, medication lists, and associated county data were also gathered to indicate prevalence, identify use trends, and map BRZ use. BRZ was found in 219 of 4,579 samples that screened positive for benzodiazepines (4.8%). Approximately half (109, 49.8%) of cases contained at least one illicit substance. A subset of samples (45, 20.5%) listed at least one prescription benzodiazepine; many of these samples reported negative for the listed medication (17, 37.8%). BRZ use was widespread in the Great Lakes region, but declined in prevalence over time. BRZ was found with illicit drugs as well as by itself, presenting a challenge in clinical settings relying on instant screening devices for benzodiazepine compliance. The observed decline in BRZ use may indicate a possible shift in drug use trends.

  • Open Access

    Trends in Tranq: prevalence of xylazine and medetomidine in oral fluid toxicology among Great Lakes States

    by Chris S. Thomas, Ankita Mondal, Matthew Levitas, Corey Widman, Bridget Lorenz-Lemberg, Dave Lemberg

    Background: Xylazine and medetomidine (each sometimes referred to as "Tranq") are animal tranquilizers commonly and sometimes unknowingly used with illegal drugs, primarily fentanyl. In the United States, xylazine appeared in the Northeast beginning in the late 2010s, preceding medetomidine beginning in 2022. Current trends in the Great Lakes region west of this origin have not been thoroughly investigated.Objectives: Identify drug use trends associated with xylazine and medetomidine specific to five states comprising the Great Lakes region.Methods: From March 2023 through May 2025, 86,093 oral fluid specimens were analyzed using liquid chromatography-tandem mass spectrometry (LC-MS-MS) following a presumptive positive screen for illegal substances using enzyme-linked immunosorbent assays (ELISA). Samples primarily originated from child protective, court, and probation services. Results and geospatial metadata from samples were used for analysis and discrete heatmap generation.Results: In xylazine- or medetomidine-positive cases, fentanyl was present over 95% of the time. Multiple drug classes were frequently detected in these cases. Each adulterant increased in prevalence among fentanyl-positive cases over their respective periods of study, converging to around 32%. Heatmaps of xylazine and medetomidine positivity rates showed that the prevalence of xylazine diminished in most states, while all states increased in prevalence for medetomidine.Conclusions: Medetomidine has been rapidly adopted as an adulterant in drug markets among Great Lakes states and is now frequently used alongside xylazine. Understanding regional trends regarding these adulterants can inform health-care professionals and policymakers of the spread and adoption of emergent drug use practices to improve public health.